File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Significance of Natural Product Derivatives and Traditional Medicine for COVID-19

TitleThe Significance of Natural Product Derivatives and Traditional Medicine for COVID-19
Authors
KeywordsSARS-CoV
coronavirus
traditional Chinese medicine
COVID-19
natural products
Issue Date2020
PublisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/processes
Citation
Processes, 2020, v. 8 n. 8, p. article no. 937 How to Cite?
AbstractCoronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there have been more than 10 million reported cases, more than 517,000 deaths in 215 countries, areas or territories. There is no effective antiviral medicine to prevent or treat COVID-19. Natural products and traditional medicine products with known safety profiles are a promising source for the discovery of new drug leads. There is increasing number of publications reporting the effect of natural products and traditional medicine products on COVID-19. In our review, we provide an overview of natural products and their derivatives or mimics, as well as traditional medicine products, which were reported to exhibit potential to inhibit SARS-CoV-2 infection in vitro, and to manage COVID-19 in vivo, or in clinical reports or trials. These natural products and traditional medicine products are categorized in several classes: (1) anti-malaria drugs including chloroquine and hydroxychloroquine, (2) antivirals including nucleoside analogs (remdesivir, favipiravir, β-D-N4-hydroxycytidine, ribavirin and among others), lopinavir/ritonavir and arbidol, (3) antibiotics including azithromycin, ivermectin and teicoplanin, (4) anti-protozoal drug, emetine, anti-cancer drug, homoharringtonine, and others, as well as (5) traditional medicine (Lian Hua Qing Wen Capsule, Shuang Huang Lian Oral Liquid, Qingfei Paidu Decoction and Scutellariae Radix). Randomized, double-blind and placebo-controlled large clinical trials are needed to provide solid evidence for the potential effective treatment. Currently, drug repurposing is a promising strategy to quickly find an effective treatment for COVID-19. In addition, carefully combined cocktails need to be examined for preventing a COVID-19 pandemic and the resulting global health concerns.
Persistent Identifierhttp://hdl.handle.net/10722/284785

 

DC FieldValueLanguage
dc.contributor.authorWang, D-
dc.contributor.authorHuang, J-
dc.contributor.authorYeung, AWK-
dc.contributor.authorTzvetkov, NT-
dc.contributor.authorHorbańczuk, JO-
dc.contributor.authorWillschke, H-
dc.contributor.authorGai, Z-
dc.contributor.authorAtanasov, AG-
dc.date.accessioned2020-08-07T09:02:36Z-
dc.date.available2020-08-07T09:02:36Z-
dc.date.issued2020-
dc.identifier.citationProcesses, 2020, v. 8 n. 8, p. article no. 937-
dc.identifier.urihttp://hdl.handle.net/10722/284785-
dc.description.abstractCoronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, there have been more than 10 million reported cases, more than 517,000 deaths in 215 countries, areas or territories. There is no effective antiviral medicine to prevent or treat COVID-19. Natural products and traditional medicine products with known safety profiles are a promising source for the discovery of new drug leads. There is increasing number of publications reporting the effect of natural products and traditional medicine products on COVID-19. In our review, we provide an overview of natural products and their derivatives or mimics, as well as traditional medicine products, which were reported to exhibit potential to inhibit SARS-CoV-2 infection in vitro, and to manage COVID-19 in vivo, or in clinical reports or trials. These natural products and traditional medicine products are categorized in several classes: (1) anti-malaria drugs including chloroquine and hydroxychloroquine, (2) antivirals including nucleoside analogs (remdesivir, favipiravir, β-D-N4-hydroxycytidine, ribavirin and among others), lopinavir/ritonavir and arbidol, (3) antibiotics including azithromycin, ivermectin and teicoplanin, (4) anti-protozoal drug, emetine, anti-cancer drug, homoharringtonine, and others, as well as (5) traditional medicine (Lian Hua Qing Wen Capsule, Shuang Huang Lian Oral Liquid, Qingfei Paidu Decoction and Scutellariae Radix). Randomized, double-blind and placebo-controlled large clinical trials are needed to provide solid evidence for the potential effective treatment. Currently, drug repurposing is a promising strategy to quickly find an effective treatment for COVID-19. In addition, carefully combined cocktails need to be examined for preventing a COVID-19 pandemic and the resulting global health concerns.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at https://www.mdpi.com/journal/processes-
dc.relation.ispartofProcesses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectSARS-CoV-
dc.subjectcoronavirus-
dc.subjecttraditional Chinese medicine-
dc.subjectCOVID-19-
dc.subjectnatural products-
dc.titleThe Significance of Natural Product Derivatives and Traditional Medicine for COVID-19-
dc.typeArticle-
dc.identifier.emailYeung, AWK: ndyeung@hku.hk-
dc.identifier.authorityYeung, AWK=rp02143-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/pr8080937-
dc.identifier.scopuseid_2-s2.0-85089224335-
dc.identifier.hkuros312514-
dc.identifier.volume8-
dc.identifier.issue8-
dc.identifier.spagearticle no. 937-
dc.identifier.epagearticle no. 937-
dc.identifier.eissn2227-9717-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats